Drug Profile

HRS 5091

Alternative Names: HRS-5091

Latest Information Update: 28 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Hengrui Medicine Co.
Class Antivirals; Sulfonamides
Mechanism of Action Nucleocapsid protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Hepatitis B

Highest Development Phases

No development reported Hepatitis B

Most Recent Events

28 Aug 2023 No recent reports of development identified for phase-I development in Hepatitis-B(Treatment-naive, Treatment-experienced) in China (PO, Tablet)
23 Jun 2022 Jiangsu HengRui Medicine completes a phase I trial in Hepatitis B (In volunteers) in China (NCT05273775)
11 May 2022 Jiangsu Hengrui Medicine plans clinical trials in Hepatitis B (PO) (Jiangsu Hengrui Medicine pipeline, May 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com